These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8185169)

  • 1. The cholecystokinin hypothesis of anxiety and panic disorder.
    Bradwejn J; Koszycki D
    Ann N Y Acad Sci; 1994 Mar; 713():273-82. PubMed ID: 8185169
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J; Koszycki D
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the significance of cholecystokinin receptors in panic disorder.
    van Megen HJ; den Boer JA; Westenberg HG
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1235-46. PubMed ID: 7863014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL; Nesse RM
    Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptides and anxiety: focus on cholecystokinin.
    Lydiard RB
    Clin Chem; 1994 Feb; 40(2):315-8. PubMed ID: 8313613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.
    Lydiard RB; Ballenger JC; Laraia MT; Fossey MD; Beinfeld MC
    Am J Psychiatry; 1992 May; 149(5):691-3. PubMed ID: 1575262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J; Koszycki D; Shriqui C
    Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia.
    Akiyoshi J; Isogawa K; Tsutsumi T; Kasturagi S; Kohno K; Furuta M; Yamamoto Y; Yamada K; Fujii I
    Biol Psychiatry; 1997 Jul; 42(2):151-4. PubMed ID: 9209734
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cholecystokinin antagonists: anxiolytic drugs of the future].
    Bourin M; Bradwejn J
    Pathol Biol (Paris); 1992 Mar; 40(3):215-7. PubMed ID: 1608663
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholecystokinin-4 and panic.
    Abelson JL; Nesse RM
    Arch Gen Psychiatry; 1990 Apr; 47(4):395. PubMed ID: 2322091
    [No Abstract]   [Full Text] [Related]  

  • 11. Glyoxalase-I mRNA expression and CCK-4 induced panic attacks.
    Eser D; Uhr M; Leicht G; Asmus M; Länger A; Schüle C; Baghai TC; Mulert C; Rupprecht R
    J Psychiatr Res; 2011 Jan; 45(1):60-3. PubMed ID: 20542521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of state and trait anxiety on the panic response to CCK-4.
    Eser D; Wenninger S; Baghai T; Schüle C; Rupprecht R
    J Neural Transm (Vienna); 2008 Jun; 115(6):917-20. PubMed ID: 18414777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
    Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is cholecystokinin a biological support in panic attacks?].
    Bourin M; Bradwejn J; Koszycki D
    Encephale; 1991; 17(5):475-9. PubMed ID: 1686250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two faces of cholecystokinin: anxiety and schizophrenia.
    Bourin M; Malinge M; Vasar E; Bradwejn J
    Fundam Clin Pharmacol; 1996; 10(2):116-26. PubMed ID: 8737954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurobiological investigations into the role of cholecystokinin in panic disorder.
    Bradwejn J
    J Psychiatry Neurosci; 1993 Jul; 18(4):178-88. PubMed ID: 8104032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The neuropeptide cholecystokinin and anxiety states].
    Cohen H; Kaplan Z
    Harefuah; 1996 May; 130(10):707-10. PubMed ID: 8794666
    [No Abstract]   [Full Text] [Related]  

  • 18. Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats.
    Bertoglio LJ; Zangrossi H
    Brain Res; 2005 Oct; 1059(1):46-51. PubMed ID: 16168394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin induces cerebral vasodilatation via presynaptic CCK2 receptors: new implications for the pathophysiology of panic.
    Sánchez-Fernández C; González C; Mercer LD; Beart PM; Ruiz-Gayo M; Fernández-Alfonso MS
    J Cereb Blood Flow Metab; 2003 Mar; 23(3):364-70. PubMed ID: 12621311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
    Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
    J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.